CASE REPORT

Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; peer review: 2 approved]

Mohan Narayanan¹², Keri Ramsey³⁴, Theresa Grebe⁵, Isabelle Schrauwen⁵³⁴, Szabolcs Szelinger³⁴, Matthew Huentelman³⁴, David Craig³⁴, Vinodh Narayanan¹⁴, C4RCD Research Group

¹Arizona Pediatric Neurology & Neurogenetics Associates, Phoenix, AZ, USA
²Barrow Neurological Institute, Phoenix, AZ, USA
³Center for Rare Childhood Disorders, Translational Genomics Research Institute, Phoenix, AZ, USA
⁴Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
⁵Department of Genetics, Phoenix Children's Hospital, Phoenix, AZ, USA

Abstract

Microcephaly is a fairly common feature observed in children with delayed development, defined as head circumference less than 2 standard deviations below the mean for age and gender. It may be the result of an acquired insult to the brain, such prenatal or perinatal brain injury (congenital infection or hypoxic ischemic encephalopathy), or be a part of a genetic syndrome. There are over 1000 conditions listed in OMIM (Online Mendelian Inheritance in Man) where microcephaly is a key finding; many of these are associated with specific somatic features and non-CNS anomalies. The term primary microcephaly is used when microcephaly and delayed development are the primary features, and they are not part of another recognized syndrome.

In this case report, we present the clinical features of siblings (brother and sister) with primary microcephaly and delayed development, and subtle dysmorphic features. Both children had brain MRI studies that showed periventricular and subcortical T2/FLAIR hyperintensities, without signs of white matter volume loss, and no parenchymal calcifications by CT scan. The family was enrolled in a research study for whole exome sequencing of probands and parents. Analysis of variants determined that the children were compound heterozygotes for nonsense mutations, c.277C>T (p.Arg93*) and c.397C>T (p.Arg133*), in the TRMT10A gene. Mutations in this gene have only recently been reported in children with microcephaly and early onset diabetes mellitus.

Our report adds to current knowledge of TRMT10A related

Open Peer Review

Reviewer Status ✔ ✔

Invited Reviewers

1. Gihan Tennekoon, Children's Hospital of Philadelphia, Philadelphia, USA
2. Ganeshwaran H. Mochida, Massachusetts General Hospital, Boston, USA

Any reports and responses or comments on the article can be found at the end of the article.
neurodevelopmental disorders and demonstrates imaging findings suggesting of delayed or abnormal myelination of the white matter in this disorder. Accurate diagnosis through genomic testing, as in the children described here, allows for early detection and management of medical complications, such as diabetes mellitus.

**Keywords**
Primary microcephaly, Delayed development, Periventricular leukomalacia, White matter hyperintensities, Diabetes mellitus, TRMT10A, tRNA methyltransferase

This article is included in the [Rare diseases](https://www.f1000research.com/journal/rare-diseases) collection.

**Corresponding authors:** Mohan Narayanan (mohan.tp2@gmail.com), Vinodh Narayanan (vnarayanan2@tgen.org)

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by donations to the Center for Rare Childhood Disorders. These include private anonymous donations. TGen also receives support from the State of Arizona. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright:** © 2015 Narayanan M et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Narayanan M, Ramsey K, Grebe T et al. Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; peer review: 2 approved] F1000Research 2015, 4:912 (https://doi.org/10.12688/f1000research.7106.1)

**First published:** 28 Sep 2015, 4:912 (https://doi.org/10.12688/f1000research.7106.1)
Clinical summary

We present case histories of siblings (a sister and brother) born to healthy non-consanguineous parents, with microcephaly and delayed development.

Patient 1

The first patient is a 12 year old girl who was born at 39 weeks gestation weighing 4 lb 10 oz, without perinatal difficulties. She was healthy as an infant, except for recurrent ear infections, which were treated with tympanostomy tubes. Hypotonia was noted during infancy, but she reached her early motor milestones, including crawling and walking, at the normal ages. Speech delay and behavioral problems were noted by 4 years of age. There was no regression. Ophthalmological evaluation was normal. Physical exam at age 4.5 years showed microcephaly, low anterior hair line, deep set eyes with mild hypotelorism, shortened forehead, and her neurological exam was normal. Head circumference was 3.5 SD below the mean for age in girls. These features have remained constant at subsequent examinations.

MRI scan of the brain showed mild FLAIR/T2 hyperintensities in the periatral white matter (Figure 1A); a CT scan did not show calcifications. Skeletal x-rays did not show any abnormality of her bones. Hearing tests, renal ultrasound, and echocardiogram were all normal. High resolution karyotype and array comparative genome hybridization (CGH) were normal. Carbohydrate deficient transferrin study, lysosomal enzymes, and 7-dehydrocholesterol level were also normal. She has not had documented hypoglycemia or hyperglycemia. Psychometric testing led to the diagnosis of mild intellectual disability. Speech and occupational therapy were provided through school and she has continued to make steady developmental progress.

Patient 2

The second patient is a 10 year old boy who was born at 36 weeks gestation weighing 5 pounds, and developed mild neonatal jaundice. The pregnancy was complicated by oligohydramnios and decreased fetal movement. He was diagnosed with hypotonia during infancy. He too achieved motor milestones at appropriate times (walked at 15 months) but speech was delayed. He had an episode of febrile status epilepticus at 17 months, and subsequent epileptic seizures without fever. Seizures have been controlled with levetiracetam (50 mg/kg/day, corresponding to 500 mg twice daily). A recent EEG showed symmetric, bilateral, frontally dominant polyspike and wave discharges, consistent with generalized epilepsy. He has a history of recurrent pulmonary infections and reactive airway disease; initial testing by CFTR gene sequencing was not conclusive and revealed only benign variants. Sweat chloride testing was abnormal on one occasion and then borderline, pancreatic elastase was normal, and a clinical diagnosis of cystic fibrosis was made. He also had recurrent otitis media that required tympanostomy tubes.

Physical examination at age 2.5 years showed small stature (5% for height and weight) microcephaly (head circumference 3 SD below mean for age), low anterior hair line, deep set eyes with mild hypotelorism, and a normal neurological exam. His phenotype was similar to his older sister, although he seemed to be more severely affected. MRI of the brain at age 2.5 years showed extensive FLAIR/T2 hyperintensities in the periventricular and subcortical white matter (Figure 1B).

The following biochemical and genetic tests were normal: array CGH, fragile X test, TORCH titers, quantitative plasma amino acids, quantitative urine organic acids, fluorescent in-situ hybridization (FISH) test for Pelizaeus-Merzbacher disease, very long chain fatty acids, enzyme assays for CLN1 (PPT1 – palmitoyl-protein thioesterase 1) and CLN2 (TPP1-tripeptidyl-peptidase 1), and 7-dehydrocholesterol. He has not had documented hypoglycemia or hyperglycemia.

His features have remained constant on follow-up examinations, with persistent microcephaly and mild hypotelorism. He is making slow progress in school with speech, occupational and physical therapy.

Figure 1. MRI findings. (1-A) – Axial MRI FLAIR image from the affected female child done at 4.5 years of age shows hyperintensities in the periventricular (primarily periatral) white matter (arrows). (1-B) Axial FLAIR and sagittal T1 MRI images from the affected male child at 2.5 years of age. This shows bilateral periventricular (periatral) and subcortical white matter hyperintensities consistent with dysmyelination (arrows). Brain architecture (corpus callosum, cerebellum, and cortical gyration) was normal.
**Ethics**

Patients and parents were enrolled into a clinical research protocol sponsored by the Translational Genomics Research Institute (TGen) approved by the Western Institutional Review Board, Protocol Number 20120789. After informed consent, blood samples were collected for DNA and RNA extraction. A separate buccal swab was sent for Sanger sequencing and independent confirmation of selected variants in a clinical laboratory (GeneDx, Gaithersburg, MD).

**Exome sequencing**

Libraries were prepared using the Illumina’s TruSeq DNA sample preparation kit and the TruSeq exome enrichment kit (Illumina, Inc., San Diego, CA, USA), following the manufacturer’s protocol. Sequencing was done by 100-bp paired-end sequencing on a HiSeq2000 instrument (Illumina, Inc., San Diego, CA, USA). Reads were aligned to the Human Genome (Hg19/GRC37) using Burrows-Wheeler transform alignment (BWA v.0.7.5). PCR duplicates were removed using Picard v.1.92, and base quality recalibration, indel realignment and single nucleotide polymorphism (SNP) and indel discovery were performed using the Genome Analysis Toolkit (GATK v.2.5-2). Variants were annotated with SnvEff 3.2a and selected (SnvStil) for protein-coding events. Prediction scores were loaded from dbNSFP and used for filtering.

**Results**

Exome sequencing identified 33,640 SNPs and indels common to the two affected individuals. The majority of these variants were common in the population, and only 4,355 were considered either novel, private or rare variants. An annotated variant file was created so that included variants in any of the four family members (male child, female child, father, and mother). Excluding UTR (untranslated region) and synonymous variants left 452 candidate variants.

There were no variants consistent with de novo mutation in both children (with presumed germline mosaicism in a parent). Four variants were identified consistent with a homozygous recessive model: SERINC2, PTH2R, SGK223, and PMP22. None of these were consistent with the clinical phenotype.

We considered an X-linked recessive model (female child less severe than male) and identified variants were in Nchs (Nance-Horan syndrome), DDX53, WAS, and TREC; four variants in RPGR. The TREC 2 variant has been reported in 83 hemizygotes in the ExAC Browser database v.0.3 (Broad Institute). The DDX53 variant is rare and has been implicated as a potential X-linked autism locus. X chromosome inactivation studies in the carrier mother have not been done.

When we considered compound heterozygous model, we identified only two variants in a single gene, TRMT10A. Both children have inherited a maternal variant encoding a nonsense mutation, c.277C>T (p.Arg93*) and a paternal variant encoding a nonsense mutation, c.397C>T (p.Arg133*). The Arg133* variant has been observed in one of 120,000 alleles in the ExAC Browser database, while the Arg93* allele has never been reported before. Based on the damaging nature of these mutations (protein truncation), consistency with an autosomal recessive model, and two previous reports of homzygous TRMT10A mutations in children with primary microcephaly, we concluded that the TRMT10A mutations were causal for our patients’ phenotype.

**Discussion**

Microcephaly is a clinical condition, rather than a specific diagnosis, defined as having a small brain size, measured by head circumference. It is generally accepted that head circumference less than 2–4 standard deviations below the mean for age and gender is considered to be microcephaly.

Primary microcephaly is either congenital and present at birth, or progressive and caused by postnatal decrease in head circumference growth rate (as in Rett syndrome, for instance). Congenital microcephaly occurs more frequently in patients born to consanguineous parents. Congenital microcephaly can be further classified by clinical and imaging features set forth by Barkovich and others. Patients with autosomal recessive primary microcephaly (MCPH) have microcephaly at birth and non-progressive mental retardation. Microcephaly with normal or simplified gyration (MSG) is thought to be a result of abnormal neuronal and glial proliferation or apoptosis.

Many genes have been implicated in the development of microcephaly (summarized in Table 1) including ASPM, MCHP1, CDS5RAP2, CEP152, CENPJ, WDR62, STIL, CASC5, CEP135, ZNF335, PHC1, CDK6, with many of them contributing to centrosome and spindle protein dysfunction during mitosis. Mutations in the ASPM gene are the most common in this group, and account for 30–40 percent of these cases. Genes implicated in primary microcephaly with associated features such as cognitive and motor impairment and epilepsy include SLC25A19, ATR, ARFGEF2, and RAB3GAP1. PYCR2 mutation described by Nakayama causes dysfunctional proline synthesis and leaves affected patients more susceptible to oxidative stress induced apoptosis, leading to postnatal microcephaly from cell death in the developing brain.

Primary microcephaly is a result of a defect in the generation of the appropriate number of neurons during early neural development. Cell division of neural progenitors in the neuroepithelium can be symmetric (generating two progenitors) or asymmetric (generating one progenitor and one post-mitotic neuron). Microcephaly has been associated with microtubule, centrosome, and mitotic dysfunctions. Dysfunction in the mitotic machinery may cause inappropriate asymmetric cell division during neurogenesis in the developing cortex and subventricular zone. Abnormal control of apoptosis during the neurogenesis phase of development can also lead to microcephaly. Studies in mice have demonstrated microcephaly due to an increase in neuronal apoptosis and depletion of the neural progenitor population. Specifically, endoplasmic reticulum stress-induced apoptosis has been shown to cause microcephaly and early onset diabetes from beta cell ER stress-induced apoptosis.

**TRMT10A and microcephaly**

TRMT10A (also known as RG9MTD2 – RNA (guanine 9)-methyltransferase domain-containing protein 2) is homologous to a yeast TRNA methyltransferase (Trm10) and methylates tRNAs at the m^G^3 position. TRMT10A is expressed in several tissues (liver, kidney, spleen, lung, fat) but at especially high levels in brain and...
Table 1. Genes causing microcephaly syndromes. This table contains a summary of selected primary microcephaly syndromes, including MCPH 1–15. Information provided includes a brief description of the phenotype, gene that is mutated, and pathogenic mechanism.

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Phenotype</th>
<th>Inheritance</th>
<th>Gene</th>
<th>Chromosome</th>
<th>Protein function/pathogenic mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCPH1</td>
<td>microcephaly, intellectual disability, epilepsy, craniofacial dysmorphism, growth retardation</td>
<td>AR</td>
<td>MCPH1</td>
<td>8p23.1</td>
<td>premature chromosomal condensation; defective G2/M checkpoint arrest, CDK1 phosphorylation</td>
</tr>
<tr>
<td>MCPH2</td>
<td>microcephaly, simplified gyration, cortical malformations, epilepsy, craniofacial dysmorphism, growth retardation</td>
<td>AR</td>
<td>WDR62</td>
<td>10q13.12</td>
<td>localized to spindle poles during mitosis</td>
</tr>
<tr>
<td>MCPH3</td>
<td>microcephaly, intellectual disability, simplified gyration, developmental and psychomotor delay, cortical malformations, craniofacial dysmorphism, hypotonia</td>
<td>AR</td>
<td>CDK5RAP2</td>
<td>9q33.2</td>
<td>centrosomal function and spindle orientation</td>
</tr>
<tr>
<td>MCPH4</td>
<td>microcephaly, intellectual disability, growth retardation</td>
<td>AR</td>
<td>CASC5</td>
<td>15q15.1</td>
<td>kinetochore protein, centromere attachment to microtubules, and spindle-assembly checkpoint signaling</td>
</tr>
<tr>
<td>MCPH5</td>
<td>microcephaly, simplified gyration, cortical malformations, intellectual disability</td>
<td>AR</td>
<td>ASPM</td>
<td>1q31.3</td>
<td>abnormal spindle gene; mitotic spindle function in neuroblasts, cleavage plane alteration, asymmetric division</td>
</tr>
<tr>
<td>MCPH6</td>
<td>microcephaly, severe intellectual disability, craniofacial dysmorphism, growth retardation</td>
<td>AR</td>
<td>CENPJ</td>
<td>13q12.12</td>
<td>centromeric protein J, microtubule assembly and nucleation</td>
</tr>
<tr>
<td>MCPH7</td>
<td>microcephaly, intellectual disability, short stature, strabismus, ataxia, epilepsy, T cell ALL</td>
<td>AR</td>
<td>STIL</td>
<td>1p33</td>
<td>neuronal cell proliferation; nuclear localization signal of TGF beta</td>
</tr>
<tr>
<td>MCPH8</td>
<td>microcephaly, craniofacial dysmorphism</td>
<td>AR</td>
<td>CEP135</td>
<td>4q12</td>
<td>fragmented centrosomes, disorganized microtubules</td>
</tr>
<tr>
<td>MCPH9</td>
<td>microcephaly, simplified gyration, psychomotor delay, jerky movements, mirror movements</td>
<td>AR</td>
<td>CEP152</td>
<td>15q21.1</td>
<td>centrosomal core protein</td>
</tr>
<tr>
<td>MCPH10</td>
<td>microcephaly, simplified gyration, cortical malformation, delayed myelination, craniofacial dysmorphism, hypertonia, spasticity</td>
<td>AR</td>
<td>ZNF335</td>
<td>20q13.12</td>
<td>zinc finger protein; neurogenesis, neuronal differentiation</td>
</tr>
<tr>
<td>MCPH11</td>
<td>microcephaly, intellectual disability, short stature</td>
<td>AR</td>
<td>PHC1</td>
<td>12p13.31</td>
<td>polycomb repressor complex; ubiquitination, proteosome-mediated degradation, chromatin remodeling</td>
</tr>
<tr>
<td>MCPH12</td>
<td>microcephaly, intellectual disability, simplified gyral pattern, craniofacial dysmorphism</td>
<td>AR</td>
<td>CDK6</td>
<td>7q21.2</td>
<td>cyclin dependent kinase, cell cycle regulation; microtubule orientation and organization</td>
</tr>
<tr>
<td>MCPH13</td>
<td>microcephaly, simplified gyration, IUGR, craniofacial dysmorphism, short stature, psychomotor delay, absent speech, spasticity, osteopenia</td>
<td>AR</td>
<td>CENPE</td>
<td>4q24</td>
<td>kinetochore associated motor protein</td>
</tr>
<tr>
<td>Syndrome</td>
<td>Phenotype</td>
<td>Inheritance</td>
<td>Gene</td>
<td>Chromosome</td>
<td>Protein function/pathogenic mechanism</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MCPH14 (OMIM#616402)</td>
<td>microcephaly, severe intellectual disability, speech delay, aggressive behavior, epilepsy, cortical malformation</td>
<td>AR</td>
<td>SASS6</td>
<td>1p21.2</td>
<td>centrosome duplication, spindle assembly; impaired centriole formation</td>
</tr>
<tr>
<td>MCPH15 (OMIM#616486)</td>
<td>microcephaly, severe intellectual disability, psychomotor delay, spastic quadriparesis, hyperreflexia, hypotonia, epilepsy, cortical malformations, early death</td>
<td>AR</td>
<td>MFSD2A</td>
<td>1p34.2</td>
<td>uptake of long chain fatty acids</td>
</tr>
<tr>
<td>Mental retardation, AD 32 (OMIM#616268)</td>
<td>microcephaly, developmental delay, craniofacial dysmorphism, cardiac defects, ocular anomalies</td>
<td>AD</td>
<td>KAT6A</td>
<td>8p11.21</td>
<td>histone acetyltransferase; dysregulation of chromatin modification</td>
</tr>
<tr>
<td>Mental retardation, AR 5 (OMIM#611091)</td>
<td>microcephaly, severe intellectual disability, craniofacial dysmorphism, short stature, hypotonia</td>
<td>AR</td>
<td>NSUN2</td>
<td>5q15.31</td>
<td>trna methyltransferase; spindle assembly during mitosis and chromosome segregation</td>
</tr>
<tr>
<td>Hypomyelinating leukodystrophy 10 (OMIM#616420)</td>
<td>microcephaly, hypomyelination, severe motor and speech delay, craniofacial dysmorphism, hypotonia</td>
<td>AR</td>
<td>PYCR2</td>
<td>1q42.12</td>
<td>pyrroline-5-carboxylate reductase; dysfunctional proline biosynthesis, oxidative stress-induced apoptosis</td>
</tr>
<tr>
<td>TAR (thrombocytopenia absent radius) syndrome (OMIM#274000)</td>
<td>severe microcephaly, defective neurogenesis, thrombocytopenia-absent radius</td>
<td>AR</td>
<td>RBM8A</td>
<td>1q21.1</td>
<td>exon-junction complex; rna metabolism in cortical development, neuronal apoptosis</td>
</tr>
<tr>
<td>Primary ciliary dyskinesia 31 (OMIM#616369)</td>
<td>microcephaly, gestational demise, craniofacial dysmorphism, renal abnormality</td>
<td>AR</td>
<td>CENPF</td>
<td>1q41</td>
<td>kinetochore and spindle; microtubule regulation, ciliogenesis</td>
</tr>
<tr>
<td>Microcephaly and chorioretinopathy - 2 (OMIM#616171)</td>
<td>microcephaly, severe intellectual disability, dwarfism, retinopathy</td>
<td>AR</td>
<td>PLK4</td>
<td>4q28.2</td>
<td>Polo-like kinase, regulator of centriole biogenesis</td>
</tr>
<tr>
<td>Wolcott-Rallison syndrome (OMIM#226980)</td>
<td>microcephaly, simplified gyration, infantile diabetes</td>
<td>AR</td>
<td>EIF2AK3</td>
<td>2p11.2</td>
<td>serine/threonine kinase; unfolded protein response, ER stress-induced apoptosis</td>
</tr>
<tr>
<td>Microcephaly, epilepsy, diabetes-MEDS (OMIM#614231)</td>
<td>microcephaly, simplified gyration, epilepsy, infantile diabetes</td>
<td>AR</td>
<td>IER3IP1</td>
<td>18q21.1</td>
<td>Immediate early response interacting protein; unfolded protein response, ER stress-induced apoptosis</td>
</tr>
<tr>
<td>Microcephaly, short stature, impaired glucose metabolism-MSSGM (OMIM#616033)</td>
<td>microcephaly, intellectual disability, short stature, adolescent onset diabetes</td>
<td>AR</td>
<td>TRMT10A</td>
<td>4q23</td>
<td>trna methyltransferase; ER stress-induced apoptosis</td>
</tr>
</tbody>
</table>

pancreatic islet cells\(^4\). Mutation of another tRNA methyltransferases, NSUN2, has been associated with microcephaly, short stature, intellectual disability, and facial dysmorphism\(^{2,3}\).

There are two previous reports of patients with homozygous nonsense or missense mutation of **TRMT10A** resulting in microcephaly. In the first report, Igoillo-Esteve and colleagues described 3 siblings, from a large consanguineous Moroccan family, with microcephaly, intellectual disability, short stature, and early-onset diabetes\(^5\). Whole exome sequencing identified a homozygous p. Arg127* nonsense mutation in the **TRMT10A** gene in the 3 affected patients; both parents and an unaffected brother were heterozygous for this mutation. Features in the oldest patient (at age 26), in addition to microcephaly and intellectual disability, included short stature, absence seizures, development of diabetes at age 22, and a variety of dysmorphic features. Brain MRI showed normal architecture and gyration. The other two children developed diabetes at age 19 and 14 respectively. The TRMT10A Arg127* mutation resulted in greatly reduced mRNA levels (presumably by nonsense-mediated decay) and absent protein levels. Loss of TRMT10A protein induced apoptosis in rat β-cells and increased stress-induced apoptosis by many endogenous molecules including high levels of glucose\(^6\).
In a second report, Gillis and colleagues described 3 siblings (one female and two male) born to healthy, non-consanguineous parents from a small, inbred Jewish community of Uzbekistan. All 3 patients suffered from microcephaly, intellectual disability, short stature, seizures, and altered glucose metabolism. The female child had delayed pubertal development and was amenorrheic at age 19 years. Exome sequencing in one affected patient followed by targeted genotyping in the rest of the family (parents, two affected sibs and 9 unaffected sibs) defined a homozygous p. Gly206Arg missense mutation in TRMT10A as causing disease in this family. All three affected patients had episodes of hypoglycemia, hyperinsulinemia, and abnormal response to glucose. Brain imaging in two of these patients was normal. The Gly206Arg mutation resulted in almost complete loss of methyltransferase activity. This suggested that decrease in methylated iRNA is responsible for growth failure, developmental delay and impaired glucose metabolism.

TRMT10A microcephaly, in contrast to primary microcephaly linked to centrosome and spindle function during mitosis, is likely related to the loss of brain volume due to increased apoptosis. TRMT10A deficiency increases the amount of beta cell apoptosis, and presumably neuronal apoptosis. The development of diabetes and abnormal glucose response may be related to endoplasmic reticulum stress-induced apoptosis induced by endogenous fatty acids and high levels of glucose. Endoplasmic reticulum stress-induced apoptosis has also been implicated in a syndrome of primary microcephaly associated with simplified gyral pattern, epilepsy, and infantile diabetes caused by mutation of the IER3IP1 gene.

Here we report two additional patients with primary (congenital) microcephaly and intellectual disability caused by compound heterozygous nonsense mutations of TRMT10A. These patients have not displayed hypoglycemia nor early onset diabetes. Brain imaging did show abnormalities in the central white matter, suggesting delayed or abnormal myelination. TRMT10A is not currently included in microcephaly gene panels available from commercial laboratories, stressing the importance of exome sequencing in the genetic diagnosis of primary microcephaly. The correct genetic diagnosis in our patients allows for anticipation and early treatment of medical complications by institution of meticulous glucose monitoring and control from an early age.

**Consent**

Written informed consent for publication of their clinical details and clinical images was obtained from the parent of the patients.

**Author contributions**

MN prepared the clinical summary and wrote the manuscript, including the discussion section, and prepared Table 1.

KR was involved in patient enrollment in the research study, review of clinical records, data analysis, clinical testing, and manuscript review and editing.

TG was involved in patient evaluation, clinical phenotyping, manuscript review, and editing. IS, SS, MH, and DC were involved in exome sequencing, data analysis, writing methods and results sections, and in manuscript review and editing.

VN was involved in patient evaluation, enrollment in the research study, review of clinical records, analysis of exome sequencing data, manuscript review and editing, and prepared Figure 1. All authors have agreed to the final content of this manuscript.

**Competing interests**

No competing interests were disclosed.

**Grant information**

This work was supported by donations to the Center for Rare Childhood Disorders. These include private anonymous donations. TGen also receives support from the State of Arizona.

*I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Acknowledgements**

The authors acknowledge the help and cooperation of the many families involved with the Center for Rare Childhood Disorders, members of the Advisory Committee of the Center for Rare Childhood Disorders, and the TGen Foundation.

The authors acknowledge the contributions of all members (current and past) of the C4RCD Research Group.

**C4RCD Research Group:**

This group includes the clinical team and laboratory research team involved in patient enrollment, sample processing, exome sequencing, data processing, preparation of variant annotation files, data analysis, validation of data, and return of research data to families. Candidate genes are identified and discussed at data analysis meetings of the entire group. The following members of the group (listed in alphabetical order) have contributed significantly to this work:

1. Newell Belnap (nbelnap@tgen.org)
2. Jason J. Corneveaux (deceased)
3. Amanda Courtright (acourtright@tgen.org)
4. David W. Craig (dcraig@tgen.org)
5. Matt de Both (mdeboth@tgen.org)
6. Brooke Hjelm (bhjelm@uci.edu)
7. Matthew J. Huentelman (mhuentelman@tgen.org)
8. Ahmet Kurdoglu (akurdoglu@tgen.org; akurdoglu@ashiondx.com)
9. Vinodh Narayanan (vnarayanan2@tgen.org)
10. Keri M. Ramsey (kramsey@tgen.org)
11. Sampathkumar Rangasamy (srangasamy@tgen.org)
12. Ryan Richholt (rrichholt@tgen.org)
13. Isabelle Schrauwen (ischrauwen@tgen.org)
14. Ashley L. Siniard (asiniard@tgen.org)
15. Szabolcs Szelingier (sszelingier@tgen.org)
Ganeshwaran H. Mochida
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

This paper describes two siblings with microcephaly and developmental delay, who were found to have compound heterozygous variants in the TRMT10A gene. Biallelic mutations of TRMT10A have recently been reported in individuals with microcephaly and abnormalities in glucose homeostasis. Seeing that only a small number of individuals reported with this condition to date, this paper adds additional insights into this condition. The technique used in this paper is standard whole-exome sequencing. Though the manuscript does not include functional studies of the identified TRMT10A variants, these variants are predicted to lead to a premature truncation of the protein and are therefore likely to be pathogenic.

I have following comments and suggestions:

- It would be helpful to include the actual physical measurements (not just standard deviations) for the affected individuals.

- It is not explicitly stated which individuals in the family had exome sequencing done and if the TRMT10A variants were confirmed by Sanger sequencing.

- Even though there seems to be only one protein isoform for TRMT10A in the public databases, the ID of the reference sequence used for annotation of the mutations should be included.

- There are several differences in clinical manifestation between the affected individuals described in this manuscript and those previously reported. Specifically, the individuals described herein do not have obvious alteration of glucose homeostasis. Also, the cerebral white matter signal abnormalities on brain MRI have not been reported previously. These features are clinically important, and it would be helpful to discuss these points more in depth.

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
TRMT10A is an tRNA (guanine) methyltransferase that is highly expressed in the pancreatic islet cells and brain. In the brain it appears expression occurs early during gestation and expression is in the dorsal telencephalon with high expression in the ventricular zone. Later there is expression in the cerebellum.

This case report describes 2 siblings where the male is more severely affected. From previous reports and these 2 cases it appears to be an autosomal recessive disorder that is characterized by mild dysmorphic features including short stature, microcephaly, non-progressive intellectual disability predominantly affecting speech, no gross for fine motor difficulties and no cerebellar dysfunction. Previous reports have not described any specific changes on the imaging studies whereas this report shows periatrial and periventricular white matter changes consistent with delayed myelination. Furthermore, neither of these children had difficulties with glucose metabolism. In term of understanding the pathophysiology of how TRMT10A brain development there is more work needed.

Nevertheless, in the setting of primary microcephaly with speech delay and abnormal glucose homeostasis, TRMT10A mutations should be considered.

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com